Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline and tDCS for cognitive enhancement in schizophrenia
2017-001357-14Phase 2Terminated
- Sponsor
- LMU Klinikum
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of varenicline in schizophrenia (4 arms), sponsored by LMU Klinikum. Primary endpoint: Change in working memory according to the n-back task. Started Jul 2017; status: terminated.
02
Drugs
varenicline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2017-001357-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001357-14.